Monteiro AR, Barbosa DJ, Remião F, Silva R. Alzheimer’s disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharm. 2023;211:115522. https://doi.org/10.1016/j.bcp.2023.115522.

Article  CAS  PubMed  Google Scholar 

Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25:5789. https://doi.org/10.3390/MOLECULES25245789.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:1–18. https://doi.org/10.1186/s13024-019-0333-5.

Article  Google Scholar 

Silva MVF, Loures CDMG, Alves LCV, De Souza LC, Borges KBG, Carvalho MDG. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26:1–11. https://doi.org/10.1186/s12929-019-0524-y.

Article  Google Scholar 

Lacosta AM, Insua D, Badi H, Pesini P, Sarasa M. Neurofibrillary tangles of Aβx-40 in Alzheimer’s disease brains. J Alzheimer’s Dis. 2017;58:661–7. https://doi.org/10.3233/JAD-170163.

Article  CAS  Google Scholar 

Durst F, Tropea C. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.

Article  Google Scholar 

Du X, Wang X, Geng M. Alzheimer’s disease hypothesis and related therapies. Transl Neurodegener. 2018;7:1–7. https://doi.org/10.1186/s40035-018-0107-y.

Article  CAS  Google Scholar 

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26:5481–503. https://doi.org/10.1038/s41380-021-01249-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLaren AMR, Kawaja MD. Olfactory dysfunction and Alzheimer’s disease: a review. J Alzheimer’s Dis. 2024;99:811–27. https://doi.org/10.3233/JAD-231377.

Article  Google Scholar 

Guo Q, Wang Z, Li H, Wiese M, Zheng H. APP physiological and pathophysiological functions: insights from animal models. Cell Res. 2012;22:78–89. https://doi.org/10.1038/cr.2011.116.

Article  CAS  PubMed  Google Scholar 

Gu L, Guo Z. Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126::305–11. https://doi.org/10.1111/jnc.12202.

Article  CAS  PubMed  Google Scholar 

Yan Y, Wang C. Aβ42 is more rigid than Aβ40 at the C terminus: implications for Aβ ggregation and toxicity. J Mol Biol. 2006;364:853–62. https://doi.org/10.1016/j.jmb.2006.09.046.

Article  CAS  PubMed  Google Scholar 

Pauwels K, Williams TL, Morris KL, Jonckheere W, Vandersteen A, Kelly G, et al. Structural basis for increased toxicity of pathological Aβ42:Aβ40 ratios in Alzheimer disease. J Biol Chem. 2012;287:5650–60. https://doi.org/10.1074/jbc.M111.264473.

Article  CAS  PubMed  Google Scholar 

Gatti L, Tinelli F, Scelzo E, Arioli F, Di Fede G, Obici L, et al. Understanding the pathophysiology of cerebral amyloid angiopathy. Int J Mol Sci. 2020;21:3435 https://doi.org/10.3390/ijms21103435.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharm Sin. 2017;38:1205–35. https://doi.org/10.1038/aps.2017.28.

Article  CAS  Google Scholar 

Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, et al. Donanemab: appropriate use recommendations. J Prev Alzheimer’s Dis. 2025;12:100150. https://doi.org/10.1016/j.tjpad.2025.100150.

Article  CAS  Google Scholar 

Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease therapeutics. Drugs. 2023;83:569–76. https://doi.org/10.1007/s40265-023-01858-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives. Transl Neurodegener. 2025;14:6. https://doi.org/10.1186/s40035-025-00465-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacorte E, Ancidoni A, Zaccaria V, Remoli G, Tariciotti L, Bellomo G, et al. Safety and efficacy of monoclonal antibodies for Alzheimer’s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimer’s Dis. 2022;87:101–29. https://doi.org/10.3233/JAD-220046.

Article  CAS  Google Scholar 

Bu XL, Rao PNP, Wang YJ. Anti-amyloid aggregation activity of natural compounds: implications for Alzheimer’s drug discovery. Mol Neurobiol. 2016;53:3565–75. https://doi.org/10.1007/s12035-015-9301-4.

Article  CAS  PubMed  Google Scholar 

Shindikar A, Singh A, Nobre M, Kirolikar S. Curcumin and resveratrol as promising natural remedies with nanomedicine approach for the effective treatment of triple negative breast cancer. J Oncol. 2016;2016:9750785. https://doi.org/10.1155/2016/9750785.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zha GF, Rakesh KP, Manukumar HM, Shantharam CS, Long S. Pharmaceutical significance of azepane based motifs for drug discovery: a critical review. Eur J Med Chem. 2019;162:465–94. https://doi.org/10.1016/j.ejmech.2018.11.031.

Article  CAS  PubMed  Google Scholar 

Pourtaher H, Hasaninejad A, Zare S, Tanideh N, Iraji A. The anti-Alzheimer potential of novel spiroindolin-1,2-diazepine derivatives as targeted cholinesterase inhibitors with modified substituents. Sci Rep. 2023;13:1–17. https://doi.org/10.1038/s41598-023-38236-0.

Article  CAS  Google Scholar 

Junkes L, Mendlowicz MV, Shader R, Nardi AE. Leo Sternbach and the benzodiazepines 60 years on: a revolutionary treatment for anxiety disorders. Pharmacol Res. 2024;207:107310. https://doi.org/10.1016/j.phrs.2024.107310.

Article  CAS  PubMed  Google Scholar 

Silva EMP, Varandas PAMM, Silva AMS. 1,4-Diazepane ring-based systems. In Ana MMM, Philips F, editors. More synthetic approaches to nonaromatic nitrogen heterocycles. 2022;1:559−84.

Boa AN, McPhillie MJ. 1,4-Diazepines. In Comprehensive Heterocyclic Chemistry IV. 2022;13:243−68.

Koch JC, Tatenhorst L, Roser AE, Saal KA, Tönges L, Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018;189:1–21. https://doi.org/10.1016/j.pharmthera.2018.03.008.

Article  CAS  PubMed  Google Scholar 

Uslaner JM, Herring WJ, Coleman PJ. The Discovery of suvorexant: lessons learned that can be applied to other CNS drug development efforts. ACS Pharm Transl Sci. 2020;3:161–8. https://doi.org/10.1021/acsptsci.9b00110.

Article  CAS  Google Scholar 

Palkowitz MD, Tan B, Roth, Bauer RA. Synthesis of diverse N-acryloyl azetidines and evaluation of their enhanced thiol reactivities. Org Lett. 2017;19:2270–3.

Article  CAS  PubMed  Google Scholar 

Bogaert AMVD, Nelissen J, Ovaere M, Meervelt LC, Compernolle F, Borggraeve WMD. Synthesis of pyridodiazepinediones by using the Ugi multicomponent reaction. Eur J Org Chem. 2010;28:5397–401.

Article  Google Scholar 

Li Y, Wang Y, Wang J. Microwave-promoted conversion of heterocyclic amines to corresponding amides under solvent-free conditions. Heterocyclic Comm. 2007;13:251–6.

Article  CAS  Google Scholar 

Ohata J. Friedel-Crafts reactions for biomolecular chemistry. Org Biomol Chem. 2024;22:3544–58. https://doi.org/10.1039/d4ob00406j.

Article  CAS  PubMed